Tick-Borne Disease Antibodies Panel, Serum
Use
This test is designed for the evaluation of the most common tick-borne diseases found in the United States, including Lyme disease, human monocytic and granulocytic ehrlichiosis, and babesiosis. It is useful for evaluating patients who have a history of or suspected tick exposure and are presenting with symptoms such as fever, myalgia, headache, and nausea. Additionally, it can be utilized in seroepidemiological surveys to understand the prevalence of these infections in various populations.
Special Instructions
Not provided.
Limitations
Serology results may be negative during the acute phase of infection, typically within 7 days post-symptom onset. Detectable IgG antibodies can appear within 7 to 10 days but may remain detectable for months to years post-infection. Cross-reactions with other Ehrlichia species may not be detected. False-negative results for Lyme disease are possible in early infection stages, and serology should not be used for treatment monitoring as IgG can persist post-infection resolution.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 87547-6 - Tick IgG + B burgdor Ab Pnl Ser
- 23877-4 - A phagocytoph IgG Titr Ser IF
- 16117-4 - B microti IgG Titr Ser
- 47405-6 - E chaffeensis IgG Titr Ser IF
- 20449-5 - B burgdor Ab Ser Ql IA
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
Not provided
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus, Heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 10 days |
| Frozen | 14 days |